The vaccine against coronavirus de Moderna was shown to be effective in teens ages 12 to 17 and showed no new or major safety concerns in a clinical trial, the firm said Tuesday, which could set the stage for a second inoculation of school-age children to be authorized. in July.

SIGHT: Seriously ill people from COVID-19 die more in Africa than in other regions of the world

Modern, whose vaccine is licensed for adults 18 and older, said it will present the findings of its adolescent study to the U.S. Food and Drug Administration (FDA). USA and other regulators for emergency use authorization in early June.

It took US regulators about a month to review a similar study from Pfizer / BioNtech, which was licensed for ages 12-15 on May 10. Yes Modern receives the same treatment, his authorization would arrive at the beginning of July.

Most children with COVID-19 they develop only mild or no symptoms but are at risk of becoming seriously ill and can transmit the virus. Widely vaccinating youth ages 12 to 18 could allow America’s schools and summer camps to relax the CDC’s suggested mask use and social distancing measures.

We are encouraged that mRNA-1273 was very effective in preventing COVID-19 in adolescents.”Said Stéphane Bancel, Moderna’s CEO, in a statement.

The essay of Modern evaluated the vaccine in 3,732 adolescents between the ages of 12 and 17, two-thirds of whom received the vaccine and one-third a placebo. The primary goal was to produce an immune response on par with that seen in the company’s large phase 3 trial in adults, which was 94.1% effective in preventing COVID-19.

SIGHT: The inequity of vaccines in the world, by Elmer Huerta

Two weeks after the second dose, the researchers found no cases of COVID-19 in the vaccine group compared to 4 cases in the placebo group, resulting in 100% vaccine efficacy, based on the company’s adult trial case definitions.

Using a case definition from the Centers for Disease Control and Prevention from USA, which requires only one symptom of COVID-19, the vaccine was found to be 93% effective, suggesting it may protect against cases with milder symptoms, the company said.

The researchers found no new security problems. The most common side effects after the second dose were headache, fatigue, body aches, and chills.

The company indicated that it is still accumulating safety data. All study participants will be observed for 12 months after their second dose to determine long-term protection and safety.

SIGHT: COVID-19 | Chile will give a “passport” for people vaccinated with two doses

Modern said it plans to submit the data to a peer-reviewed publication. The company is currently testing its vaccine in children up to 6 months of age.

Besides in USA, the Pfizer vaccine is also licensed for use in adolescents 12-15 years of age in Canada and Algeria.

RECOMMENDED VIDEO

IT MAY INTEREST YOU

  • How long should I wait to get vaccinated if I already got COVID-19?
  • Bolivia’s new bet against COVID-19: donkey plasma serum
  • Coronavirus in India | “The COVID-19 meme that almost made me leave my family WhatsApp group”
  • Pfizer Vaccine Creator Envisions 75% Protection Against Variant Discovered in India
  • COVID-19 Vaccine: What Happens If I Don’t Get My Second Dose?
  • COVID-19 | How is the posterior syndrome suffered by patients who have overcome the disease?
  • Pfizer and Moderna Vaccines Effective Against Indian Variants, Study Finds
  • Europe approves that Pfizer’s vaccine can be kept for a month in a refrigerator
  • Scientists urge the world to clean the air, a means of transmission of the coronavirus
  • Antibodies that neutralize COVID-19 remain in the blood for at least eight months

.

Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more

Then24

The News 24 is the place where you get news about the World. we cover almost every topic so that you don’t need to find other sites.